These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35984628)

  • 41. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
    Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study.
    Sharman J; Kabadi SM; Clark J; Andorsky D
    Br J Haematol; 2021 Feb; 192(4):737-746. PubMed ID: 33095453
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
    Jain P; Romaguera J; Srour SA; Lee HJ; Hagemeister F; Westin J; Fayad L; Samaniego F; Badillo M; Zhang L; Nastoupil L; Kanagal-Shamanna R; Fowler N; Wang ML
    Br J Haematol; 2018 Aug; 182(3):404-411. PubMed ID: 29785709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
    Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
    Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.
    Ruella M; Soubeyran P
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):432-436. PubMed ID: 27913512
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
    Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
    N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
    Martin P; Bartlett NL; Blum KA; Park S; Maddocks K; Ruan J; Ridling L; Dittus C; Chen Z; Huang X; Inghirami G; DiLiberto M; Chen-Kiang S; Leonard JP
    Blood; 2019 Mar; 133(11):1201-1204. PubMed ID: 30692121
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma.
    Lee YP; Jung YJ; Cho J; Ko YH; Kim WS; Kim SJ; Yoon SE
    Blood Res; 2023 Dec; 58(4):208-220. PubMed ID: 38151961
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
    Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Li L; Zhang L; Newberry K; Ou Z; Cheng N; Fang B; McGreivy J; Clow F; Buggy JJ; Chang BY; Beaupre DM; Kunkel LA; Blum KA
    N Engl J Med; 2013 Aug; 369(6):507-16. PubMed ID: 23782157
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma.
    Goyal RK; Jain P; Nagar SP; Le H; Kabadi SM; Davis K; Kaye JA; Du XL; Wang M
    Leuk Lymphoma; 2021 Jun; 62(6):1325-1334. PubMed ID: 33966583
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
    Maruyama D; Nagai H; Fukuhara N; Kitano T; Ishikawa T; Nishikawa T
    J Clin Exp Hematop; 2019; 59(2):98-100. PubMed ID: 31257351
    [No Abstract]   [Full Text] [Related]  

  • 52. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
    Siddiqi T; Coutre S; McKinney M; Barr PM; Rogers K; Mokatrin A; Valentino R; Szoke A; Deshpande S; Zhu A; Arango-Hisijara I; Osei-Bonsu K; Wang M; O'Brien S
    Leuk Lymphoma; 2022 Jul; 63(7):1580-1588. PubMed ID: 35227147
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
    Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
    Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
    January
    Prescrire Int; 2016 Apr; 25(170):89-92. PubMed ID: 27183765
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.
    Baggio D; Wellard C; Chung E; Talaulikar D; Keane C; Opat S; Giri P; Minson A; Cheah CY; Armytage T; Lee D; Chong G; Johnston A; Cochrane T; Waters N; Hamad N; Wood EM; Hawkes EA
    Leuk Lymphoma; 2023 Mar; 64(3):621-627. PubMed ID: 38376128
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.
    Le Gouill S; Morschhauser F; Chiron D; Bouabdallah K; Cartron G; Casasnovas O; Bodet-Milin C; Ragot S; Bossard C; Nadal N; Herbaux C; Tessoulin B; Tchernonog E; Rossi C; McCulloch R; Gastinne T; Callanan MB; Rule S
    Blood; 2021 Feb; 137(7):877-887. PubMed ID: 33181832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Fraser G; Cramer P; Demirkan F; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Pavlovsky MA; Karlsson C; Hallek M; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Chanan-Khan A
    Leukemia; 2019 Apr; 33(4):969-980. PubMed ID: 30315239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
    McCulloch R; Visco C; Eyre TA; Frewin R; Phillips N; Tucker DL; Quaglia FM; McMillan A; Lambert J; Crosbie N; Rule S
    Br J Haematol; 2020 May; 189(4):684-688. PubMed ID: 32011729
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status.
    Huang Q; Deering KL; Harshaw Q; Leslie LA
    Adv Ther; 2022 Jul; 39(7):3292-3307. PubMed ID: 35608754
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hyperleukocytosis increases risk of fatal hyperkalemia with new ibrutinib/venetoclax regimen for refractory mantle cell lymphoma.
    Verma A; Mbughuni M; Mariash E; Mesa H
    J Chemother; 2019; 31(7-8):428-431. PubMed ID: 31738653
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.